Repligen Launches Innovative AVIPure dsRNA Resin Columns
WALTHAM, Mass. — Repligen Corporation (NASDAQ:RGEN), a leader in life sciences focused on bioprocessing technologies, has recently unveiled its latest offering: the AVIPure dsRNA Clear OPUS columns. This advancement aims to revolutionize the production of mRNA therapeutics and vaccines by simplifying processes and enhancing overall efficiency.
Transforming mRNA Therapeutic Production
The AVIPure dsRNA Clear resin stands out due to its unique affinity chromatography capability which integrates seamlessly with Repligen's highly-regarded OPUS pre-packed columns. This innovative technology showcases an exceptional ability to eliminate double-stranded RNA (dsRNA) impurities from transcribed RNA, which is crucial in achieving high drug efficacy. The increasing demand for mRNA-based biologics underlines the importance of effective dsRNA removal techniques, and Repligen's new offering addresses this pressing demand.
Meeting Market Needs
As the biopharmaceutical landscape continues to evolve, manufacturers are presented with the challenge of producing mRNA therapeutics with maximum effectiveness while minimizing potential immune responses. The AVIPure dsRNA Clear OPUS columns provide a dependable solution within a convenient closed system tailored for mRNA producers. This addresses a significant market need for an effective method to purify mRNA.
About the AVIPure dsRNA Clear Technology
In the launch, Olivier Loeillot, President and CEO of Repligen, expressed excitement about this breakthrough technology, noting that it represents the first phase of multiple resin introductions planned for the coming year. The AVIPure dsRNA Clear resin merges proprietary affinity ligands with Tantti's advanced DuloCore bead technology. Remarkably, this method can achieve a 2-3 log reduction of dsRNA impurities in merely one minute of flow-through, eliminating the need for heat or solvents typically required by traditional purification methods.
Enhanced Manufacturing Efficiency
This advanced resin not only simplifies the purification process but also ensures it can be easily scaled for larger manufacturing needs. Efficiencies gained from this technology can lead to substantial cost reductions while providing the high-purity mRNA required for effective therapeutic development. The pre-packed OPUS columns integrate effortlessly into existing biomanufacturing workflows, making them a versatile choice for producers.
Commitment to Quality Biotherapeutics
Further commenting on the technology, Umay Saplakoglu, VP of Product Management, stated that this innovative solution tackles one of the significant barriers in mRNA therapeutic production. By combining speed with substantial impurity removal capabilities, the AVIPure dsRNA Clear OPUS columns are poised to simplify workflows while maintaining safety and high-quality standards for biotherapeutics.
About Repligen Corporation
As a global leader in life sciences, Repligen Corporation is dedicated to developing and commercializing bioprocessing technologies that enhance the manufacturing of biological drugs. Their focus on innovative solutions supports biopharmaceutical developers and contract manufacturing organizations (CDMOs) worldwide. Established in Waltham, Massachusetts, the company operates multiple manufacturing locations in the U.S. and Europe, ensuring a broad reach in supporting bioprocessing advancements.
Frequently Asked Questions
What is the AVIPure dsRNA Clear OPUS column?
The AVIPure dsRNA Clear OPUS column is a novel affinity chromatography solution designed to enhance the production and purification of mRNA therapeutics by effectively removing dsRNA impurities.
How does the AVIPure technology benefit mRNA production?
This technology provides significant advantages in speed, scalability, and impurity removal, which simplifies the manufacturing process for mRNA-based therapeutics, ultimately improving drug efficacy.
What are the primary applications for AVIPure dsRNA Clear columns?
The columns are primarily aimed at mRNA manufacturers seeking to produce high-quality therapeutics and vaccines with minimal impurities, thus ensuring better patient outcomes.
Who is behind the development of the AVIPure columns?
Repligen Corporation has developed the AVIPure columns, integrating technology from Tantti Laboratory Inc. to enhance bioprocessing capabilities.
Where can I learn more about Repligen Corporation?
For additional information regarding Repligen and its innovative bioprocessing solutions, visit Repligen's official website or their professional social media channels.
